Literature DB >> 16328088

New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.

Makoto Tanno1, Ichiro Nakamura, Shunsuke Kobayashi, Kumiko Kurihara, Katsumi Ito.   

Abstract

Therapies aimed at inhibiting tumor necrosis factor, a proinflammatory cytokine implicated in autoimmune disease, are effective for rheumatoid arthritis (RA) and Crohn's disease. We report two patients who newly developed multiple demyelinating lesions in the central nervous system in the course of infliximab therapy for active RA. Neurological symptoms and the number of gadolinium-diethylenetriamine pentaacetic acid-enhanced lesions in magnetic resonance imaging gradually diminished with steroid treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16328088     DOI： 10.1007/s10067-005-0097-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  12 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

Review 2.  The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire.

Authors:  A Cope; R Ettinger; H McDevitt
Journal:  Res Immunol       Date:  1997-06

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Onset of multiple sclerosis associated with anti-TNF therapy.

Authors:  N L Sicotte; R R Voskuhl
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

5.  TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

Authors: 
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

Review 6.  Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.

Authors:  A Raza
Journal:  Microsc Res Tech       Date:  2000-08-01       Impact factor: 2.769

7.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

8.  Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.

Authors:  M K Sharief; R Hentges
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

9.  Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors.

Authors:  K W Selmaj; C S Raine
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

10.  Tumor necrosis factor identified in multiple sclerosis brain.

Authors:  F M Hofman; D R Hinton; K Johnson; J E Merrill
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307
View more
  19 in total

1.  Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Authors:  Ali Theibich; Lene Dreyer; Melinda Magyari; Henning Locht
Journal:  Clin Rheumatol       Date:  2013-11-08       Impact factor: 2.980

Review 2.  New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Authors:  Takumi Matsumoto; Ichiro Nakamura; Ayumi Miura; Gen Momoyama; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2012-11-14       Impact factor: 2.980

3.  Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Alexandre; Yves Vandermeeren; Olivier Dewit; Tom Moreels; Nanne de Boer; Anjan Dhar; Chris Ziady; Ariella Bar-Gil Shitrit; Flavio Steinwurz; Njegica Jojic; Giuseppe Costantino; Benoit Bihin; Jean-François Rahier; Konstantinos H Katsanos
Journal:  J Crohns Colitis       Date:  2016-01-12       Impact factor: 9.071

Review 4.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

Review 5.  Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.

Authors:  Jens Watzlawik; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2010-03       Impact factor: 4.618

Review 6.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

Review 7.  Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.

Authors:  Sueli Carneiro; Penelope Esther Palominos; Sônia Maria Alvarenga Anti; Rodrigo Luppino Assad; Rafaela Silva Guimarães Gonçalves; Adriano Chiereghin; Andre Marun Lyrio; Antônio Carlos Ximenes; Carla Gonçalves Saad; Célio Roberto Gonçalves; Charles Lubianca Kohem; Cláudia Diniz Lopes Marques; Cláudia Goldenstein Schainberg; Eduardo de Souza Meirelles; Gustavo Gomes Resende; Lenise Brandao Pieruccetti; Mauro Waldemar Keiserman; Michel Alexandre Yazbek; Percival Degrava Sampaio-Barros; Ricardo da Cruz Lage; Rubens Bonfiglioli; Thauana Luíza Oliveira; Valderílio Feijó Azevedo; Washington Alves Bianchi; Wanderley Marques Bernardo; Ricardo Dos Santos Simões; Marcelo de Medeiros Pinheiro; Cristiano Barbosa Campanholo
Journal:  Adv Rheumatol       Date:  2021-11-24

8.  Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.

Authors:  Waka Yokoyama; Kazuki Takada; Nobuyuki Miyasaka; Hitoshi Kohsaka
Journal:  BMJ Case Rep       Date:  2014-08-01

9.  Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.

Authors:  Alexander Winkelmann; Robert Patejdl; Sabine Wagner; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.